Key result
Ivabradine added to bisoprolol safely improves angina in a patient with severe IHD and COPD.
Why the study?
The association of COPD and ischaemic heart disease is challenging regarding prognosis and pharmacological treatment, as patients often do not receive beta-blockers due to fear of adverse effects.
Does the addition of ivabradine to a beta-blocker improve angina symptoms without worsening pulmonary function in a patient with ischemic heart disease and COPD?
Case Report (n=1)
Does the addition of ivabradine to a beta-blocker improve angina symptoms without worsening pulmonary function in a patient with ischemic heart disease and COPD?
Answers are grounded in this paper and cite their sources.
Ivabradine may be a safe and effective option for controlling angina symptoms in patients with concomitant ischemic heart disease and COPD who cannot tolerate beta-blocker uptitration.
The association of chronic obstructive pulmonary disease (COPD) and ischaemic heart disease (IHD) is challenging both in terms of prognosis and of pharmacological treatment. An 83-year-old Caucasian male patient has chronic kidney disease, COPD, previous myocardial infarction, coronary artery bypass graft with left internal mammary artery (LIMA) on left anterior descending (LAD), saphenous vein graft (SVG) on obtuse marginal (OM)1 and on right coronary artery, and percutaneous coronary intervention (PCI) on LAD (occlusion of LIMA) and on SVG for OM1 (SVG critical stenosis). Recently, the patient complained worsening angina [Canadian Cardiovascular Society (CCS) III] and had residual ischaemia in the anterior wall after an unsuccessful attempt of PCI was performed on LAD for in-stent occlusion due to restenosis. Bisoprolol uptitration failed due to worsening of pulmonary function at spirometry. For this reason, ivabradine 5 mg b.i.d. was added to bisoprolol. Afterwards, the patient referred amelioration of symptoms and he is actually in CCS Class I. The control spirometry showed moderate obstruction comparable to his chronic situation. Patients with IHD and COPD often do not receive β-blockers due to the fear of adverse effects. However, cardioselective β-blockers do not worsen pulmonary function while they reduce mortality in COPD patients. In this setting, ivabradine could be extremely helpful in order to control symptoms since it is effective in patients with asthma and COPD, with no alteration in respiratory function or symptoms and improves exercise capacity and functional class in COPD patients.
No takes yet. Share an insight, caveat, or question.
Biscaglia et al. (2019) conducted a case report in Angina and chronic obstructive pulmonary disease (n=1). Ivabradine added to bisoprolol was evaluated on Amelioration of angina symptoms (CCS Class). Addition of ivabradine b.i.d. to bisoprolol improved angina symptoms from CCS Class III to Class I without worsening pulmonary function in an 83-year-old man with severe IHD and COPD.
Synapse has enriched 10 related papers. Consider them for comparative context: